{"id":56819,"date":"2026-02-10T23:57:45","date_gmt":"2026-02-10T15:57:45","guid":{"rendered":"https:\/\/flcube.com\/?p=56819"},"modified":"2026-02-10T23:57:46","modified_gmt":"2026-02-10T15:57:46","slug":"hemony-pharma-partners-with-insud-pharma-to-advance-fourth-generation-oral-contraceptive-in-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=56819","title":{"rendered":"Hemony Pharma Partners with Insud Pharma to Advance Fourth-Generation Oral Contraceptive in China"},"content":{"rendered":"\n

Hemony Pharmaceutical Co., Ltd.<\/strong> has entered a strategic partnership<\/strong> with Insud Pharma<\/strong>, a leading Spanish pharmaceutical company<\/strong>, to jointly advance drospirenone and ethinylestradiol tablets<\/strong> in the China market<\/strong>. The fourth-generation combined oral contraceptive<\/strong> leverages drospirenone’s unique anti-mineralocorticoid and anti-androgenic properties<\/strong> to differentiate from traditional hormonal contraceptives in the $2+ billion China family planning market<\/strong>.<\/p>\n\n\n\n

Partnership Structure<\/h2>\n\n\n\n
Element<\/th>Detail<\/th><\/tr><\/thead>
Chinese Partner<\/strong><\/td>Hemony Pharmaceutical Co., Ltd.<\/td><\/tr>
Spanish Partner<\/strong><\/td>Insud Pharma<\/td><\/tr>
Asset<\/strong><\/td>Drospirenone and ethinylestradiol tablets (3mg\/0.03mg)<\/td><\/tr>
Drug Class<\/strong><\/td>Fourth-generation combined oral contraceptive (COC)<\/td><\/tr>
Territory<\/strong><\/td>China (joint advancement and commercialization)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Product Profile & Clinical Differentiation<\/h2>\n\n\n\n
Feature<\/th>Drospirenone-Ethinyl Estradiol Specification<\/th>Competitive Advantage<\/th><\/tr><\/thead>
Progestin Generation<\/strong><\/td>Fourth-generation<\/strong> (17-\u03b1-spirolactone derivative)<\/td>Latest hormonal technology vs. legacy levonorgestrel\/norethisterone<\/td><\/tr>
Anti-Mineralocorticoid Activity<\/strong><\/td>Unique among progestins<\/strong><\/td>Reduces water\/sodium retention and weight gain<\/strong>\u2014top patient concern<\/td><\/tr>
Anti-Androgenic Effects<\/strong><\/td>Mild testosterone antagonism<\/strong><\/td>Improves acne, hirsutism; appeals to cosmetic-conscious demographic<\/td><\/tr>
Tolerability Profile<\/strong><\/td>Lower incidence<\/strong> of GI discomfort and breakthrough bleeding<\/td>Improved continuation rates vs. traditional COCs<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Context & Strategic Positioning<\/h2>\n\n\n\n
Factor<\/th>Market Implication<\/th><\/tr><\/thead>
China Contraceptive Market<\/strong><\/td>>30 million women<\/strong> use oral contraceptives; market growing at 8-10% CAGR<\/strong> driven by urbanization and family planning policy evolution<\/td><\/tr>
Drospirenone Heritage<\/strong><\/td>Yaz\/Yasmin<\/strong> (Bayer) established premium positioning<\/strong>; patent expiry creates biosimilar\/brand-generic opportunity<\/strong> for Insud\/Hemony entry<\/td><\/tr>
Weight Gain Concern<\/strong><\/td>#1 reason for COC discontinuation<\/strong> in China; drospirenone’s anti-mineralocorticoid profile<\/strong> directly addresses this unmet need<\/td><\/tr>
Insud Pharma Strategy<\/strong><\/td>Spanish company with strong Latin American and European women’s health presence<\/strong>; China partnership enables Asia-Pacific expansion<\/strong><\/td><\/tr>
Hemony Market Access<\/strong><\/td>Local partner provides regulatory expertise, distribution infrastructure, and hospital\/GP channel relationships<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Development & Commercial Outlook<\/h2>\n\n\n\n
Phase<\/th>Activity<\/th>Timeline<\/th><\/tr><\/thead>
Current<\/strong><\/td>Partnership execution; technology transfer and CMC alignment<\/td>Q1 2026<\/td><\/tr>
Regulatory<\/strong><\/td>NMPA registration submission (reference to Yasmin\/Yaz bioequivalence or bridging studies)<\/td>2026<\/td><\/tr>
Approval<\/strong><\/td>Marketing authorization for contraceptive indication<\/td>2026-2027<\/td><\/tr>
Launch<\/strong><\/td>Joint commercialization with differentiated “weight-friendly” positioning<\/td>2027<\/td><\/tr>
Expansion<\/strong><\/td>Potential acne\/polycystic ovary syndrome label extensions<\/td>Post-approval<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Forward\u2011Looking Statements<\/strong>
This brief contains forward\u2011looking statements regarding drospirenone-ethinyl estradiol regulatory approval timelines, China market penetration, and competitive positioning against Bayer’s established brands. Actual results may differ due to NMPA bioequivalence requirements, pricing pressure in China’s contraceptive market, and consumer brand loyalty to legacy products.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Hemony Pharmaceutical Co., Ltd. has entered a strategic partnership with Insud Pharma, a leading Spanish…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[4436,4608],"class_list":["post-56819","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-hemony-pharmaceutical","tag-insud-pharma"],"yoast_head":"\nHemony Pharma Partners with Insud Pharma to Advance Fourth-Generation Oral Contraceptive in China - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Hemony Pharmaceutical Co., Ltd. has entered a strategic partnership with Insud Pharma, a leading Spanish pharmaceutical company, to jointly advance drospirenone and ethinylestradiol tablets in the China market. The fourth-generation combined oral contraceptive leverages drospirenone's unique anti-mineralocorticoid and anti-androgenic properties to differentiate from traditional hormonal contraceptives in the $2+ billion China family planning market.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=56819\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hemony Pharma Partners with Insud Pharma to Advance Fourth-Generation Oral Contraceptive in China\" \/>\n<meta property=\"og:description\" content=\"Hemony Pharmaceutical Co., Ltd. has entered a strategic partnership with Insud Pharma, a leading Spanish pharmaceutical company, to jointly advance drospirenone and ethinylestradiol tablets in the China market. The fourth-generation combined oral contraceptive leverages drospirenone's unique anti-mineralocorticoid and anti-androgenic properties to differentiate from traditional hormonal contraceptives in the $2+ billion China family planning market.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=56819\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-10T15:57:45+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-10T15:57:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56819#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56819\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Hemony Pharma Partners with Insud Pharma to Advance Fourth-Generation Oral Contraceptive in China\",\"datePublished\":\"2026-02-10T15:57:45+00:00\",\"dateModified\":\"2026-02-10T15:57:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56819\"},\"wordCount\":373,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Hemony Pharmaceutical\",\"Insud Pharma\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56819#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56819\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=56819\",\"name\":\"Hemony Pharma Partners with Insud Pharma to Advance Fourth-Generation Oral Contraceptive in China - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-02-10T15:57:45+00:00\",\"dateModified\":\"2026-02-10T15:57:46+00:00\",\"description\":\"Hemony Pharmaceutical Co., Ltd. has entered a strategic partnership with Insud Pharma, a leading Spanish pharmaceutical company, to jointly advance drospirenone and ethinylestradiol tablets in the China market. The fourth-generation combined oral contraceptive leverages drospirenone's unique anti-mineralocorticoid and anti-androgenic properties to differentiate from traditional hormonal contraceptives in the $2+ billion China family planning market.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56819#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56819\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56819#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hemony Pharma Partners with Insud Pharma to Advance Fourth-Generation Oral Contraceptive in China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Hemony Pharma Partners with Insud Pharma to Advance Fourth-Generation Oral Contraceptive in China - Insight, China's Pharmaceutical Industry","description":"Hemony Pharmaceutical Co., Ltd. has entered a strategic partnership with Insud Pharma, a leading Spanish pharmaceutical company, to jointly advance drospirenone and ethinylestradiol tablets in the China market. The fourth-generation combined oral contraceptive leverages drospirenone's unique anti-mineralocorticoid and anti-androgenic properties to differentiate from traditional hormonal contraceptives in the $2+ billion China family planning market.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=56819","og_locale":"en_US","og_type":"article","og_title":"Hemony Pharma Partners with Insud Pharma to Advance Fourth-Generation Oral Contraceptive in China","og_description":"Hemony Pharmaceutical Co., Ltd. has entered a strategic partnership with Insud Pharma, a leading Spanish pharmaceutical company, to jointly advance drospirenone and ethinylestradiol tablets in the China market. The fourth-generation combined oral contraceptive leverages drospirenone's unique anti-mineralocorticoid and anti-androgenic properties to differentiate from traditional hormonal contraceptives in the $2+ billion China family planning market.","og_url":"https:\/\/flcube.com\/?p=56819","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-10T15:57:45+00:00","article_modified_time":"2026-02-10T15:57:46+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=56819#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=56819"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Hemony Pharma Partners with Insud Pharma to Advance Fourth-Generation Oral Contraceptive in China","datePublished":"2026-02-10T15:57:45+00:00","dateModified":"2026-02-10T15:57:46+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=56819"},"wordCount":373,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Hemony Pharmaceutical","Insud Pharma"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=56819#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=56819","url":"https:\/\/flcube.com\/?p=56819","name":"Hemony Pharma Partners with Insud Pharma to Advance Fourth-Generation Oral Contraceptive in China - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-02-10T15:57:45+00:00","dateModified":"2026-02-10T15:57:46+00:00","description":"Hemony Pharmaceutical Co., Ltd. has entered a strategic partnership with Insud Pharma, a leading Spanish pharmaceutical company, to jointly advance drospirenone and ethinylestradiol tablets in the China market. The fourth-generation combined oral contraceptive leverages drospirenone's unique anti-mineralocorticoid and anti-androgenic properties to differentiate from traditional hormonal contraceptives in the $2+ billion China family planning market.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=56819#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=56819"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=56819#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Hemony Pharma Partners with Insud Pharma to Advance Fourth-Generation Oral Contraceptive in China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56819","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=56819"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56819\/revisions"}],"predecessor-version":[{"id":56821,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56819\/revisions\/56821"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=56819"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=56819"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=56819"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}